M Bartl1, J Winkelmann2,3,4, B Högl5, W Paulus6, C Trenkwalder7,8. 1. Klinik für Klinische Neurophysiologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland. michael.bartl@med.uni-goettingen.de. 2. Institut für Neurogenomik Helmholtz Zentrum München, 85764, Neuherberg, Deutschland. 3. Neurologische Klinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, 81675, München, Deutschland. 4. Munich Cluster for Systems Neurology (SyNergy), München, Deutschland. 5. Universitätsklinik für Neurologie, Medizinische Universität Innsbruck, Anichstraße 35, 6020, Innsbruck, Österreich. 6. Klinik für Klinische Neurophysiologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland. 7. Zentrum für Parkinson-Syndrome und Bewegungsstörungen, Paracelsus-Elena Klinik, Klinikstr. 16, 34128, Kassel, Deutschland. 8. Klinik für Neurochirurgie, Universitätsmedizin Göttingen, Robert Koch Str. 40, 37075, Göttingen, Deutschland.
Abstract
BACKGROUND: Restless legs syndrome (RLS) is a common neurological disease. Studies have shown that RLS is associated with a variety of medical and neurological disorders. OBJECTIVES: Using the example of three associated neurological diseases, the significance for everyday therapy decisions is assessed. MATERIAL AND METHODS: A systematic search was carried out in PubMed for all studies with the keyword "RLS" in combination with polyneuropathies (PNP), Parkinson's disease (PD) and multiple sclerosis (MS) and classified according to the methodology in high, medium or low study quality. RESULTS: Of 16 studies on RLS and MS, 10 were rated as "high". The high association frequency of RLS in MS between 13.3% and 65.1% (the variability possibly originates from different methods) prevents further statements about the prevalence. Within 30 studies on Parkinson's disease 17 were classified as having a high quality. In patients with Parkinson disease RLS occurs most frequently during therapy and is related to the duration of dopaminergic treatment. In patients with polyneuropathy, only 5 out of 24 studies were classified as being of high quality and an increased RLS prevalence was detected for acquired polyneuropathies with heterogeneous data for hereditary forms. CONCLUSION: There is an increased prevalence of association with RLS for the diseases discussed. This prevalence is possibly determined by the pathophysiology of these disorders. These diseases are possibly characterized by genetic predispositions as well, which can hopefully be classified more accurately in the future.
BACKGROUND:Restless legs syndrome (RLS) is a common neurological disease. Studies have shown that RLS is associated with a variety of medical and neurological disorders. OBJECTIVES: Using the example of three associated neurological diseases, the significance for everyday therapy decisions is assessed. MATERIAL AND METHODS: A systematic search was carried out in PubMed for all studies with the keyword "RLS" in combination with polyneuropathies (PNP), Parkinson's disease (PD) and multiple sclerosis (MS) and classified according to the methodology in high, medium or low study quality. RESULTS: Of 16 studies on RLS and MS, 10 were rated as "high". The high association frequency of RLS in MS between 13.3% and 65.1% (the variability possibly originates from different methods) prevents further statements about the prevalence. Within 30 studies on Parkinson's disease 17 were classified as having a high quality. In patients with Parkinson disease RLS occurs most frequently during therapy and is related to the duration of dopaminergic treatment. In patients with polyneuropathy, only 5 out of 24 studies were classified as being of high quality and an increased RLS prevalence was detected for acquired polyneuropathies with heterogeneous data for hereditary forms. CONCLUSION: There is an increased prevalence of association with RLS for the diseases discussed. This prevalence is possibly determined by the pathophysiology of these disorders. These diseases are possibly characterized by genetic predispositions as well, which can hopefully be classified more accurately in the future.
Authors: Wayne A Hening; Richard P Allen; Mystinna Washburn; Suzanne R Lesage; Christopher J Earley Journal: Sleep Med Date: 2009-01-29 Impact factor: 3.492
Authors: Richard P Allen; Daniel L Picchietti; Diego Garcia-Borreguero; William G Ondo; Arthur S Walters; John W Winkelman; Marco Zucconi; Raffaele Ferri; Claudia Trenkwalder; Hochang B Lee Journal: Sleep Med Date: 2014-05-17 Impact factor: 3.492
Authors: Richard P Allen; Crystal Chen; Diego Garcia-Borreguero; Olli Polo; Sarah DuBrava; Jeffrey Miceli; Lloyd Knapp; John W Winkelman Journal: N Engl J Med Date: 2014-02-13 Impact factor: 91.245
Authors: Abdul Qayyum Rana; Abdullah A Mosabbir; Abdul Rehman M Qureshi; Muhammad Abbas; Mohammad A Rana Journal: Neurol Res Date: 2016-03-30 Impact factor: 2.448
Authors: Jan Rémi; Thomas Pollmächer; Kai Spiegelhalder; Claudia Trenkwalder; Peter Young Journal: Dtsch Arztebl Int Date: 2019-10-11 Impact factor: 5.594